Pancreatitis

April 5, 2018

Pancreatic Cancer Lawsuits Over Januvia, Byetta, and Victoza moving again

Pancreatic Cancer Lawsuits Over Januvia, Byetta, and Victoza moving again. Byetta, Januvia, and Victoza lawsuits are back on track over Pancreatic Cancer claims with the recent Ninth Circuit Court of Appeals rulings.

The federal appeals court reactivated more than 750 Byetta, Januvia, Janumet, and Victoza lawsuits brought by folks diagnosed with pancreatic cancer, from the use of these medications.

Unfortunately, popular type 2 diabetic medications Byetta, Victoza, Januvia, and Janumet have been linked to an increased risk of pancreatitis and pancreatic cancer. Plaintiffs blame the drug makers who they allege knew about the development of pancreatic cancer in many cases, yet failed to warn patients and the doctors.

July 27, 2017

Actemra Serious Heart and Lung Injuries

by Dr. Shezad Malik

Actemra Serious Heart and Lung Injuries. Many newer rheumatoid arthritis drugs have strong including black box warnings about the risk of heart attack, stroke, heart failure, lung disease, and other injuries but Actemra Serious Heart and Lung Injuries warning was not issued by the drug maker when the medication was introduced.

According to recent reports, Actemra Serious Heart and Lung Injuries may be the same, if not a higher, risk of these injuries. As a result of the failure to warn about these side effects, Actemra lawsuits may provide financial compensation for injured patients nationwide.

What is Actemra?

January 5, 2014

California Byetta, Januvia Pancreatic Cancer Lawsuits

by Dr. Shezad Malik

All Byetta, Januvia, Janumet and Victoza cancer lawsuits are consolidated and centralized as part of an MDL, or Multidistrict Litigation.

These product liability cases involve pancreatic cancer after the use of Byetta, Januvia, Janumet or Victoza as part of the “Incretin Mimetics Product Liability Litigation.”

September 2, 2013

Byetta, Januvia Pancreatic Cancer Lawsuits

by Dr. Shezad Malik

The U.S. Judicial Panel on Multidistrict Litigation (JPML) has agreed to consolidate all Byetta, Januvia, Janumet and Victoza cancer lawsuits, centralizing the litigation as part of an MDL, or Multidistrict Litigation. The JPML issued a Transfer Order on August 26, and these product liability cases involve pancreatic cancer after the use of Byetta, Januvia, Janumet or Victoza as part of the “Incretin Mimetics Product Liability Litigation.”

The product liability cases will be centralized before U.S. District Judge Battaglia in the Southern District of California for coordinated handling during pretrial proceedings. The consolidation is beneficial for all parties in complex pharmaceutical litigation, to reduce repetative discovery and to prevent conflicting rulings from different federal judges.

What are Incretin Mimetics?

August 12, 2013

Cancer Risk with Byetta and Januvia Downplayed by FDA

by Dr. Shezad Malik

According to the FDA, there is no scientific evidence to confirm that a group of type 2 diabetes drugs called GLP-1 inhibitors is linked to pancreatic cancer. The FDA decision comes on the heels of the European Medicines Agency, which stated that they have been unable to confirm an increased risk of pancreatic cancer linked to side effects of Byetta, Januvia, Janumet, Victoza and other incretin mimetic drugs.

The FDA has apparently completed its safety review into the new group of medications, known as incretin mimetics, and is preparing to report that it has found no conclusive connection between the medications and pancreatic cancer. According to the EMA, its experts reviewed the data and found “methodological limitations and potential sources of bias” and decided the available data don’t bear out worries about an increased risk of “pancreatic adverse events.”

The report addresses the entire group of incretin mimetics, which comprises GLP-1 agonists, which mimic a key hormone, and DPP-4 inhibitors, which interfere with a protein that breaks down the same hormone.

June 14, 2013

Concerns About Byetta, Januvia and Victoza Drug Safety

by Dr. Shezad Malik

The National Institutes of Health held a workshop, addressing the risks associated with the newer diabetic drugs. These medications, known as Incretic Mimetics are coming under fire for alleged increased risk of pancreatic cancer.

Merck & Co., Novo Nordisk A/S and others, the manufacturers of these drugs may be asked to collect more data on a potential cancer link even as they try to reassure U.S. regulators this week of the drugs’ safety.

The Food and Drug Administration said it is considering setting up a study, either through the agency or the companies, that looks deeper into whether medicines for Type 2 diabetes, including Merck’s Januvia and Bristol Myers-Squibb Co.’s Byetta, cause pancreatic cell growth that could turn cancerous.